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Cancer cells must carefully regulate their metabolism to maintain growth and division under varying nutrient
and oxygen levels. Compelling data support the investigation of numerous enzymes as therapeutic targets to
exploit metabolic vulnerabilities common to several cancer types. We discuss the rationale for developing
such drugs and review three targets with central roles in metabolic pathways crucial for cancer cell growth:
pyruvate kinase muscle isozyme splice variant 2 (PKM2) in glycolysis, glutaminase in glutaminolysis, and
mutations in isocitrate dehydrogenase 1 and 2 isozymes (IDH1/2) in the tricarboxylic acid cycle. These targets
exemplify the drugging approach to cancermetabolism, with allostericmodulation being the common theme.
The first glutaminase andmutant IDH1/2 inhibitors have entered clinical testing, and early data are promising.
Cancer metabolism provides a wealth of novel targets, and targeting allosteric sites promises to yield selec-
tive drugs with the potential to transform clinical outcomes across many cancer types.The development of cancer is driven by the acquisition of multi-
ple alterations in normal human cells that allow dysregulated
proliferation. These alterations encompass a broad spectrum
of biological processes including cell growth, epigenetic regula-
tion of gene expression, and cell metabolism (Hanahan and
Weinberg, 2011). The specific metabolic requirements of cancer
cells are driven by interplay between their genetic and epigenetic
status and the microenvironment; thus, the metabolic machinery
must carefully regulate energy use to maintain growth and divi-
sion under conditions of varying nutrient and oxygen levels.
Some of the central metabolic pathways utilized by cancer cells
are illustrated in Figure 1. Neighboring stromal cells and normal
tissues compete with the tumor for nutrients and paradoxically,
in some cases, provide critical signals and nutrients. Addition-
ally, genetic mutations alter the utilization of, or dependence
on, nutrients according to the tumor suppressor or oncogene
affected (Cairns et al., 2011; Yuneva et al., 2012). The crosstalk
between the signaling pathways of these genetic alterations
and the metabolic machinery of the cell is complex and only
partially understood at present (Ward and Thompson, 2012).
In this review, we discuss the rationale for developing drugs
that target cancer cell metabolism, and provide in-depth discus-
sion on three cancer metabolism targets that exemplify the drug-
ging approach: pyruvate kinase (PK) in glycolysis, glutaminase in
the glutaminolysis pathway, and isocitrate dehydrogenase (IDH)
in the tricarboxylic acid (TCA) cycle. We aim to highlight the com-
mon theme of allosteric modulation in designing drugs against
these targets, which have central roles in metabolic pathways
that are crucial for cancer cell growth, with a focus on the inter-
face between chemistry and biology.
Rationale for Targeting Cancer Cell Metabolism
Early work in cancer metabolism includes not only the much-
cited work by Otto Warburg in the 1920s, describing the propen-Chemistry & Biology 2sity of cancer cells for glycolysis, but also groundbreaking work
by Farber and others in the 1940s on the use of antifolates in the
clinic as efficacious anticancer agents (Farber and Diamond,
1948; Warburg et al., 1927). In the 1960s and 1970s, work with
the glutamine analogs, acivicin and 6-diazo-5-oxo-1-norleucine
(DON), introduced the possibility of therapeutic benefit through
inhibition of glutamine pathways in cancer cells (Ahluwalia
et al., 1990). The 1970s also saw the emergence of asparaginase
therapy for the treatment of childhood acute lymphoblastic leu-
kemia, which is still in use today, as removal of circulating aspar-
agine halts the growth of asparagine-dependent leukemic cells
(Avramis, 2011).
Glycolysis is probably the best-understood metabolic path-
way in cancer cells. Many cancers utilize glucose for ATP pro-
duction and as a means of providing carbon for the pentose
phosphate, serine, and 1-carbon pathways (Figure 1). Glycolysis
is regulated directly by multiple growth factor pathways and by
tumor microenvironment, including hypoxia. Compelling data
exist to support the investigation of several enzymes in the
pathway as drug targets including hexokinase 2 (Muller et al.,
2012), enolase 2 (Muller et al., 2012), and the muscle isozyme
of PK (PKM) (Christofk et al., 2008a). We will focus on PKM, in
particular the alternative splice variant, PKM2, which has been
shown to be critical for cancer cell proliferation (Anastasiou
et al., 2012; Christofk et al., 2008a; Kung et al., 2012).
In recent years, glutamine biology has become an area of
intense research as a greater appreciation for its role in cancer
cell homeostasis has emerged. Glutaminase has been impli-
cated as a critical node in cancer cells, and glutamine depen-
dence has been described in multiple settings, including triple
negative breast cancer (Gross et al., 2014; Timmerman et al.,
2013) and renal cell carcinoma (Metallo et al., 2012).
While PKM2 and glutaminase represent interesting therapeu-
tic targets, the genes encoding these enzymes have yet to be1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1143
Figure 1. Central Metabolic Pathways
Utilized by Cancer Cells
*denotes mutated isoenzyme.
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degree. In contrast, several metabolic genes have been identi-
fied as frequently mutated in cancer. For example, homozygous
loss of function mutations in the TCA cycle enzymes succinate
dehydrogenase and fumarate hydratase are observed inmultiple
cancers (Raimundo et al., 2011), and accumulation of their
metabolites (fumarate and succinate) in deficient tumors are
thought to impact pathways capable of driving tumorigenesis
(Adam et al., 2014; Kaelin, 2011). Mutations in another TCA cycle
enzyme, IDH, have also garnered much interest and excitement.
IDH mutations are prevalent in glioma (70% of low-grade
gliomas and secondary glioblastomas) (Yan et al., 2009) and
acute myeloid leukemia (AML; up to 20% of all patients)
(McKenney and Levine, 2013), and have been identified in other
cancers including lymphoma (Cairns et al., 2012), cholangiocar-
cinoma (Borger et al., 2012), and chondrosarcoma (Amary et al.,
2011). IDH mutations are often identified in founding clones
of AML and are likely to be disease initiating, highlighting
their importance as drug targets (Welch et al., 2012). IDH1/2
inhibitor discovery efforts are ongoing, as the first wave of these
drugs has recently entered clinical trials, as detailed later in this
review.
Based on knowledge acquired to date, there is no doubt that
cancer metabolism provides a wealth of novel therapeutic tar-
gets and multiple innovative ways in which to exploit metabolic
vulnerabilities for therapeutic benefit. More comprehensive re-
views cover the breadth of metabolic targets that are currently
under investigation (Stine and Dang, 2013; Vander Heiden,
2011). The following sections of this review focus on PKM2,1144 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedglutaminase, and mutated IDH1/2 as
exemplary metabolism targets under
investigation for development of cancer
therapies.
Drugging Glycolysis: Targeting
Pyruvate Kinase Muscle Isozyme
Alternative Splice Variant 2
PK catalyzes the last step of glycolysis,
converting phosphoenolpyruvate (PEP)
to pyruvate, while producing one mole-
cule of ATP. The reaction encompasses
two chemical steps: the first involves a
phosphoryl transfer from PEP to ADP,
forming an enolate intermediate and
ATP, and the second involves proton-
ation of the enolate intermediate, forming
pyruvate (Robinson and Rose, 1972).
PKM2 is one of four PK isoforms in hu-
mans. PKM1 and PKM2 result from the
alternative splicing of exons 9 and 10 of
the PKM gene, which encode a stretch
of amino acids that differ at 23 positions
between PKM1 and PKM2. PKM1 isconstitutively active in skeletal muscle and brain tissue, but is
not allosterically regulated. PKM2 is expressed in fetal and prolif-
erating tissues, has low basal activity compared with PKM1, and
is allosterically regulated. R-type pyruvate kinase (PKR) and
L-type pyruvate kinase (PKL) are transcribed via different pro-
moters from the PKLR gene. PKR is expressed in erythrocytes
and PKL in the liver. PKR, PKL, and PKM1 exist as stable tetra-
mers, whereas PKM2 forms tetramers (high activity form), dimers
(low activity form), and monomers (Mazurek, 2011).
Pyruvate Kinase Muscle Isozyme Alternative Splice
Variant 2 in Cancer Cell Metabolism
Cancer cells predominantly express PKM2, which can be down-
regulated by tyrosine kinase growth factor signaling pathways,
allowing metabolic flexibility. Phosphotyrosine peptides have
been shown to suppress PKM2 activity by binding tightly to
PKM2, thereby catalyzing the release of fructose 1,6-bisphos-
phate (FBP), resulting in a switch to the low activity dimer state
(Christofk et al., 2008b; Hitosugi et al., 2009). This downregula-
tion is thought to support tumor growth and proliferation by
allowing for the shunting of glycolytic intermediates toward other
biosynthetic pathways (i.e., pentose phosphate and serine path-
ways). In keeping with this model, the activation of PKM2 in
cancer cells using small molecule agonists resulted in serine
auxotrophy (Kung et al., 2012). Consistent with the hypothesis
that PKM2 is a critical metabolic switch, there is growing evi-
dence that, depending on the cellular stress environment,
PKM2 activity can be regulated by posttranslational modification
such as acetylation (Lv et al., 2011), phosphorylation (Hitosugi
Figure 2. Three Different Metabolic
Enzymes and Their Allosteric Inhibitors
Protomers are depicted as cartoon ribbons in
blue, green, yellow, and cyan. Synthetic allostery
is depicted in stick format with red highlight.
(A) Structure of tetrameric PKM2:AGI-980 (4:2
complex) from PDB 4G1N. AGI-980 is shown in
stick rendering near the center of tetramer. Each
PK monomer consists of four domains, usually
designated A, B, C, and N (Dombrauckas et al.,
2005). The tetramer is a dimer-of-dimers with
approximate D2 symmetry. The dimer is formed
between the A domains of each monomer, while
the tetramer is formed via dimerization along the
C subunit interfaces of each dimer. The active site
of PKM2 lies within a cleft between the A and B
domain, illustrated by a PEP analog (red spheres).
The FBP binding pocket is located entirely within
the C domain (pink spheres). The natural allosteric
site of serine is also shown (black spheres).
(B)TetramericGAC:BPTES (4:2complex) fromPDB
3UO9.Glutamatemolecules are shownas spheres.
(C) Dimeric IDH2R140Q:AGI-6780 (2:1 complex)
from PDB 4JA8 (Wang et al., 2013). NADP mole-
cules are shown as spheres.
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proline hydroxylation (Luo et al., 2011).
The utility of PKM2 activators in the clinic has yet to be deter-
mined, but recent work with tumor xenografts with a PKM2 acti-
vator suggests that this may be a viable approach (Parnell et al.,
2013). As PKM2 tetramers show greater than 50-fold higher
activity than PKM2 monomers (Anastasiou et al., 2012), one
consideration when designing drugs to activate PKM2 for thera-
peutic means would be the need for small-molecule ligands
capable of driving the enzyme toward its optimally active tetra-
meric form, thus forcing cancer cells into a less flexiblemetabolic
state.
Structure of Pyruvate Kinase Muscle Isozyme
Alternative Splice Variant 2
The structure of the PKM2 tetramer is summarized in Figure 2A.
PKM2 is allosterically activated in a ‘‘feedforward’’ manner by
the upstream glycolytic metabolite, FBP, which induces a shift
to the active tetrameric conformation (Christofk et al., 2008b;
Dombrauckas et al., 2005). PKM2 can be independently alloste-
rically activated by serine (Chaneton et al., 2012), which binds in
a distinct pocket that can also accommodate the inhibitor
phenylalanine (Protein Data Bank [PDB] ID: 4FXJ). The binding
of phenylalanine results in a tetrameric form distinct from the
active conformer (Morgan et al., 2013). It is not clear how the
change from serine to phenylalanine elicits such a dramatic
change in protein behavior, or whether there is any biological
interaction between serine activation and phenylalanine inhibi-
tion of PKM2 in cancer cells. Of note, PKM1 and PKL/R are not
activated by serine, despite the conservation of the serine bind-
ing site in all PK isoforms.Chemistry & Biology 21, September 18, 2014 ªDiscovery of Allosteric Activators
of Pyruvate Kinase Muscle Isozyme
Alternative Splice Variant 2
A number of small molecules that
potently activate PKM2 have beendiscovered by various groups (Table 1). Interestingly, all seven
X-ray co-complexes currently available show compounds bound
at a novel binding pocket distinct from the FBP and serine bind-
ing sites, which would otherwise allow cells to overcome nega-
tive regulation by phosphotyrosines (Kung et al., 2012). The
compounds found in structures 3GQY, 3GR4 (Boxer et al.,
2010), 3H6O (Jiang et al., 2010), 3ME3, and 3U2Z (Anastasiou
et al., 2012) were identified by screening the NIH Small Molecule
Repository, and can be classified into two distinct chemical
series, both of which establish very similar interactions with
PKM2 (Table 1). Analogues in these two classes selectively acti-
vated PKM2 allosterically with good selectivity against PKM1,
PKL, and PKR (Anastasiou et al., 2012; Boxer et al., 2010; Jiang
et al., 2010). The molecule found in the structure 4JPG (Guo
et al., 2013) is similar to the two series described above, where
the pyrimidone ring is found between the two Phe26 residues
(Table 1). Interestingly, the activator found in the 4G1N structure
(Kung et al., 2012) sits in the same pocket as the NIH com-
pounds. However, the interactions are quite different, with the
side chains of the two Phe26 that line the pocket assuming
distinct conformations. This activator wraps around the two aro-
matic residues, which pushes it closer to the walls of the pocket,
allowing for a richer series of interactions with PKM2 (Table 1).
There are two additional series of PKM2 activators that have
been reported for which no structural information is available
(Table 1) (Parnell et al., 2013; Xu et al., 2014; Yacovan et al.,
2012). Members of this series were shown to have an activation
level comparable to that of FBP, with selectivity for PKM2 over
PKL, PKR, and PKM1.
PKM2 offers a very interesting example of an allosterically
regulated enzyme. Different allosteric sites have so far been2014 Elsevier Ltd All rights reserved 1145
Table 1. Biochemical Properties of Small Molecule PKM2 Inhibitors
Series PDB ID Ligand Reference Binding Characteristics
Substituted N,N’-
diarylsulfonamide
3GQY (Boxer et al.,
2010)
d All completely buried within
A-A’ interface, 35A˚ from FBP
pocket
d Binding pocket lined with
residues equivalent to those of
PKM2 molecules forming A-A’
interface
d All sandwiched between phenyl
rings of the two Phe26 from
different monomers
d All additionally interact with
side chain of Phe26 through
slightly distorted T-shaped p-p
interactions (two such
interactions for substituted N,N0-
diarylsulfonamides and one for
thieno[3,2-b]pyrrole[3,2-d]
pyridazinones)
3GR4 (Boxer et al.,
2010)
3ME3
 
(Anastasiou
et al., 2012)
Thieno[3,2-b]pyrrole
[3,2-d]pyridazinone
3H6O (Jiang et al.,
2010)
3U2Z (Anastasiou
et al., 2012)
2-((1H-benzo[d]imidazol-
1-yl)methyl)-4H-pyrido
[1,2-a]pyrimidin-4-ones
4JPG (Guo et al.,
2013)
d Pyrimidone ring found between
the two Phe26 residues forming
p-p interactions with the
aromatic rings
d Carbonyl interacts with a
bridging water molecule
d Benzimidazole reaches a region
of the activator pocket that is not
occupied in any of the published
crystal structures
d One of the imidazole nitrogens
forms an H-bond with Lys311,
which is normally part of a salt
bridge to Asp354
(Continued on next page)
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Table 1. Continued
Series PDB ID Ligand Reference Binding Characteristics
Quinolone sulfonamides 4G1N (Kung et al.,
2012)
d Quinoline moiety sits on a flat,
mainly apolar surface defined by
Phe26, Leu27 and Met30 from
chain A and Phe26, Tyr390 and
Leu394 from chain A’
d One of the two oxygen atoms of
the sulfonamide accepts an H-
bond from the backbone oxygen
of Tyr390, the other interacts with
a water molecule
d The oxygen of the amide moiety
forms an H-bond with side-chain
nitrogen of Lys311
d Terminal aromatic ring sits in
the other copy of the quinoline
pocket
d Aromatic rings of the side
chains of the two Phe26 lining the
pocket almost perpendicular (not
parallel); activator wrapped
around the two aromatic residues
3-(trifluoromethyl)-1H-
pyrazole-5-carboxamide
-
 
(Parnell et al.,
2013; Xu et al.,
2014)
d Cocrystal structure of one
compound bound to tetrameric
PKM2 obtained but file not
available for download from PDB:
described as bound to the
allosteric site at the dimer–dimer
interface
5-((2,3-dihydrobenzo[b]
[1,4]dioxin-6-yl)sulfonyl)-2-
methyl-1-(methylsulfonyl)
indoline scaffold
-
N
S
O
O
S
O
O
N
H
O
O
(Yacovan
et al., 2012)
d Cocrystal structure of one
compound bound to PKM2
obtained but not available for
download from the PDB:
described as bound to dimer
interface
d Interactions very similar to
those established by thieno
[3,2-b]pyrrole[3,2-d]pyridazinone
series above
- Indicates not available.
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small-molecule ligands) and all activate PKM2 by stabilizing
the tetrameric form. It is remarkable that molecules as small as
serine can dramatically alter this protein’s conformational land-
scape and aggregation state and lead to an active enzyme.
This unusual allosteric site revealed by the small-molecule
ligands is of particular curiosity, largely because neither its func-
tion nor its native ligands are known. All of the drug-like activa-
tors described above bind at the dimer–dimer interface and
seem to act by displacing water from the mainly apolar pocket,
thus contributing to the stabilization of the tetramer. While these
PKM2 activators show promising preclinical data, none have yet
entered clinical development.Chemistry & Biology 2Drugging Glutaminolysis: Targeting the Glutaminase C
Variant
Glutaminase catalyzes the conversion of glutamine to glutamate
and ammonia. Glutamate can be oxidized to a-ketoglutarate
(aKG), which then anaplerotically feeds into the TCA cycle as a
means of providing proliferating cells with biosynthetic interme-
diates and ATP (Figure 1); glutamate is also used as a substrate
for the generation of glutathione, which provides protection from
redox stress (Hensley et al., 2013; Shanware et al., 2011). The
ammonia produced during the reaction can be used in certain
tissues like the kidney to provide pH homeostasis, and nitrogen
derived from glutamine is utilized in nucleotide biosynthetic and
glycosylation pathways.1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1147
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coded by two different genes, GLS1 (kidney-type) and GLS2
(liver-type). GLS1 has two full length splice variants, K-gluta-
minase (KGA) and glutaminase C (GAC).
Glutaminase in Cancer Cell Metabolism
Glutamine metabolism is higher in cancer cells than in normal
cells, and glutaminase activity correlates with tumor growth rates
(Hensley et al., 2013; Shanware et al., 2011). Some cancers
are dependent on glutamine for survival, and tumor cells in cul-
ture have shown oncogene-associated glutamine dependency
(Hensley et al., 2013; Yuneva et al., 2007). GLS1 expression
has been shown to be positively regulated by c-Myc (Gao
et al., 2009), while GLS2 is positively regulated by p53 (Hu
et al., 2010). Curiously, GLS1 expression seems to predominate
over GLS2 in most cancers, although several studies indicate a
significant role for GLS2 in tumor biology (Qing et al., 2012).
The inhibition of glutaminase activity has been shown to delay
tumor growth in several models (Hensley et al., 2013), sug-
gesting that glutaminase inhibition is a reasonable therapeutic
approach.
Structure of Glutaminase
Glutaminase is a tetramer with four active sites (Figure 2B),
although from a protein structure perspective it can be consid-
ered a dimer of dimers. The dimer:tetramer equilibrium may
play a role in regulating its physiological activity (Kenny et al.,
2003). In all crystal structures, glutamate and glutamine bind in
the same way, forming an extensive set of H-bond interactions
within the active site (PDB 3UO9 and 3VOZ) (DeLaBarre et al.,
2011; Thangavelu et al., 2012). The enzymatic mechanism in-
volves the formation of an acyl enzyme intermediate between
an active site serine residue and substrate glutamine. Hydrolysis
of this intermediate results in the liberation of ammonia and
glutamate.
Identification of Allosteric Inhibitors of Glutaminase
The first crystal structure of a glutaminase–inhibitor complex
was that of the prokaryotic form of GAC in complex with DON,
a natural product of soil bacteria, which formed a covalent inter-
action with the serine residue that forms an acyl enzyme interme-
diate in the normal reaction (Brown et al., 2008; Ortlund et al.,
2000). Recently, a co-complex of DON and the catalytic domain
of human GLS1 has been obtained (Thangavelu et al., 2014);
however, no large changes were observed between the bound
and unbound forms of the enzyme. DON itself has been investi-
gated as a therapeutic option for glutaminase inhibition; how-
ever, clinical development was hampered by insufficient efficacy
at achievable doses and severe dose-limiting toxicities (Ahluwa-
lia et al., 1990). Current therapeutic evaluation of this molecule is
focused on its combined use with other agents such as pegy-
lated glutaminase (Mueller et al., 2008).
Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide
(BPTES) is perhaps the best described preclinical reference in-
hibitor of glutaminase (Robinson et al., 2007). Mechanism of
action studies indicated that it affected formation of the gluta-
minase tetramer, potentially through an allosteric mechanism.
The allosteric nature of BPTES inhibition was confirmed when
it was solved in complex with the full length GAC splice variant1148 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Lt(DeLaBarre et al., 2011). BPTES binds at a set of loops at the
interface of the two dimers (Figure 2B). Interestingly, sequence
variations in these loops lead to the abrogation of GLS1-specific
inhibition by BPTES. When the two GLS1 residues are mutated
into corresponding GLS2 residues (F318Y and F322S), the
mutant GLS1 enzyme becomes resistant to BPTES inhibition.
While it is clear that the mechanism is allosteric in nature, the
exact mode of BPTES inhibition of glutaminase remains elusive.
The altered position of the interfacial loops interacting with
BPTES is close to the active site, but does not appear to affect
the overall conformation of catalytic residues in the active site.
Interestingly, the phosphate response of GLS1 was also altered
in the loop mutants. This suggests that the loops may be
altering the electrostatics of the active site. BPTES was also
shown to disrupt the activated higher-order oligomeric forma-
tion of glutaminase (Ferreira et al., 2013). Regardless of the
nature of allostery, such a detailed X-ray structure has enabled
the synthesis of analogs, one of which had similar potency but
improved solubility compared with BPTES, and demonstrated
good tumor efficacy in mouse xenografts (Table 2) (Shukla
et al., 2012).
Perhaps the most promising compound in the BPTES class
is CB-839 (Calithera’s glutaminase inhibitor), which is currently
in clinical trials (Table 2). Although no co-complex structure
has been reported for CB-839, its chemical similarity to BPTES
suggests a similar inhibitor binding pocket. Tumor types with
elevated dependence on glutamine express GAC at high levels,
and there appears to be an association between this marker
and sensitivity to inhibition by BPTES-derived molecules.
Triple-negative breast cancer cell lines that have high GAC
expression and an increased dependence on extracellular
glutamine for growth were the most sensitive to CB-839 (Gross
et al., 2014).
In addition to DON and BPTES-based molecules, other
inhibitors of glutaminase have been identified, but their mech-
anism of inhibition is not well characterized. Computational
docking studies suggested a dibenzophenanthridine series
of glutaminase inhibitors, exemplified by compound 968
(Table 2) (Katt et al., 2012; Wang et al., 2010), may be binding
to an interface between the two monomers rather than the
glutamine binding pocket, but experimental evidence for this
is still lacking.
Drugging the Tricarboxylic Acid Cycle: TargetingMutant
Isocitrate Dehydrogenase 1 and Isocitrate
Dehydrogenase 2
Wild-type IDH1/2 catalyzes the conversion of isocitrate to aKG
with concomitant reduction of nicotinamide adenine dinucleo-
tide phosphate (NADP+) to nicotinamide adenine dinucleotide
phosphate, reduced (NADPH) and release of CO2 (Figure 1). As
there are very few pathways to produce NADPH (an essential
cellular reducing factor against oxidative stress damage), the
key biological role of IDH may be the production of NADPH
rather than contribution to the aKG pool. Kinetically, the oxida-
tive decarboxylating ‘‘forward’’ reaction of the IDH1 isozyme ex-
hibits random sequential ordered kinetics (Pietrak et al., 2011).
However, in the reductive or ‘‘reverse’’ direction, albeit at a
very slow rate, the wild-type enzyme can either be carboxylating
or noncarboxylating. Reductive carboxylation appears to bed All rights reserved
Table 2. Characteristics of Small Molecule Glutaminase Inhibitors
Series Molecule Characteristics Efficacy Data
BPTES N-(5–[1,3,4]thiadiazol-2-
yl)-2-phenylacetamide 6
(Shukla et al., 2012)
d Similar potency but better water solubility vs. BPTES d Attenuated growth of P493
human lymphoma B cells
in vitro
d Diminished tumor growth in
P493 tumor xenograft SCID
mice with no apparent toxicity
CB-839 (Calithera)
(Gross et al., 2014)
d Orally bioavailable
d Binds at allosteric sites of GLS1 KGA and GAC
d Potent, selective, time-dependent reversible
inhibition with slow recovery time
d Anti-proliferative activity
(double-digit nM potency)
in cellular proliferation assays
in wide range of tumors
d Currently in Phase I trials
of locally-advanced/metastatic
refractory solid tumors (triple-
negative breast cancer,
NSCLC, RCC, mesothelioma)
and hematological cancers
[Clinicaltrials.gov:
NCT02071927, NCT02071862,
NCT02071888]
Dibenzophenanthridines Compound 968
(Katt et al., 2012;
Wang et al., 2010)
d Modest potency in the low mM concentrations
d Loses all inhibitory activity against glutaminase
activated by preincubation with inorganic phosphate
(phosphate does not affect BPTES potency)
d Anti-proliferative activity in
breast cancer cell line at
10 mmol/L concentration
NSCLC, nonsmall cell lung cancer; RCC, renal cell carcinoma.
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glutamine to feed aKG into lipid synthesis under hypoxic condi-
tions (Wise et al., 2011).
There are three isoforms of IDH. IDH1 is located in both the
peroxisome and the cytosol, whereas IDH2 and IDH3 are located
inmitochondria. It is unclear what the relative contributions of the
IDH2 and IDH3 isoforms are to overall mitochondrial TCA func-
tion. IDH1 and IDH2 are both obligatory homodimeric proteins
and use NADP+ as a cofactor, whereas IDH3 uses NAD+ as a
cofactor and is a heterotrimeric protein comprising alpha, beta,
and gamma subunits. All three isozymes require either Mg2+ or
Mn2+ as divalent metal cofactors for catalysis. The dimeric struc-
ture of IDH2 is shown in Figure 2C.Chemistry & Biology 2Mutant Isocitrate Dehydrogenase in Cancer Cell
Metabolism
The role of IDH mutations in cancer metabolism was recognized
following the observation of frequent and recurrent mutations of
IDH1 and IDH2 in patients with glioma and AML, initially identi-
fied by genomic deep sequencing and subsequent comparative
genetic analyses (Parsons et al., 2008; Yan et al., 2009). These
mutations were originally characterized as loss of function (Mar-
dis et al., 2009; Parsons et al., 2008; Yan et al., 2009), suggesting
that mutated IDH acts as a tumor suppressor due to the loss of
catalytic conversion of isocitrate to aKG (Zhao et al., 2009). How-
ever, with the exception of cases of haploinsufficiency, the het-
erozygous mutation pattern of IDH is more consistent with an1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1149
Figure 3. Simplified Description of IDH
Protein Motion
The large domain (residues 1–103 and 286–414)
forms nearly all of the NADPH cofactor binding
residues and roughly half of the substrate binding
residues. The small domain (residues 104–136 and
186–285) contains the remaining substrate bind-
ing residues and the metal binding residues. The
interface between the two protomers is formed
by both the small domain and the clasp region
(residues 137–185). The large domain moves
away from the small domain to facilitate NADPH
cofactor exchange and substrate binding. The
large domain then closes up against the small
domain, thereby completing the substrate binding
pocket and bringing the cofactor, substrate, and
metal into close contact with each other and with
the key catalytic residues to facilitate hydride
transfer between substrate and cofactor and
enzyme-assisted carboxylation/decarboxylation.
Subsequent opening of the large domain from the
small domain would enable product release and
cofactor exchange to complete the catalytic cycle
(Rendina et al., 2013; Xu et al., 2004).
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possess the neomorphic activity to generate the oncometabo-
lite, 2-hydroxyglutarate (2HG) (Dang et al., 2009; Gross et al.,
2010; Ward et al., 2010). With a single codon substitution, the
kinetic properties of the mutant IDH isozyme are significantly
altered, resulting in an obligatory sequential ordered reaction in
the reverse direction (Rendina et al., 2013). Indeed, the critical
kinetic observation of mutant IDH was not only the loss of
affinity for isocitrate, but also a dramatic increase in NADPH
affinity by three orders of magnitude (Dang et al., 2009), suggest-
ing a substantial change in protein dynamics imparted by the
mutation.
The only known homeostatic 2HG clearancemechanism is the
relatively inefficient reconversion of 2HG back to aKG by D-2-
hydroxyglutarate dehydrogenase. Therefore, 2HG accumulates
when over-produced by mutant IDH. 2HG itself has been shown
to be sufficient to drive the malignant phenotype (Rakheja et al.,
2013). Abnormally high 2HG levels impair aKG-dependent diox-
ygenases through competitive inhibition, including those that
modify DNA and histones (i.e., Jumonji domain-containing his-
tone demethylases and the ten-eleven translocation (TET) family
of 50-methylcytosine hydroxylases) (Chowdhury et al., 2011; Fig-
ueroa et al., 2010), as well as EglN prolyl hydroxylase in regu-
lating hypoxia-inducible factor (Losman et al., 2013). This results
in altered epigenetic status that blocks cell differentiation. These
findings, combined with the inhibitory effects of fumarate and
succinate on the same families of aKG-dependent enzymes,
highlight a critical and fascinating network that ties together cen-
tral metabolic pathways and epigenetic control. Remarkably,
mutations in TET2 are mutually exclusive with IDH mutations in
AML, strongly suggesting that, in this context, the tumorigenic
effects of 2HG are at least in part driven by inhibition of TET2.
The precise targets of IDH mutations with associated 2HG pro-
duction (and TET2 mutations) that promote tumorigenesis are
currently unknown; however, it is clear that IDH1/2 and TET2mu-
tations lead to a block in hematopoietic cell differentiation (Fig-
ueroa et al., 2010; Lu et al., 2012; Moran-Crusio et al., 2011;
Wang et al., 2013). To date, no IDH3 mutation associated with
cancer has been reported (Krell et al., 2011; Reitman and Yan,1150 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Lt2010), suggesting that the role of IDH1/2 has a greater impact
on tumorigenesis.
Targeting mutated isoforms of IDH1/2 therefore presents a
logical approach to cancer therapy. A consideration in designing
such drugs is the heterozygous somatic nature of the IDH1/2mu-
tation, which likely yields a mixture of homo- and heterodimers;
statistically, heterodimers should be the major species in vivo.
Mutant homodimers and wild-type-mutant heterodimers both
efficiently catalyze the production of 2HG from aKG (Dang
et al., 2009; Rendina et al., 2013). However, the heterodimer is
potentially more oncogenic, as it is more efficient at producing
2HG than homodimeric mutants (Pietrak et al., 2011) due to an
increased local concentration of substrate while conserving
NADPH. The heterodimer as a molecular target therefore be-
comes an important consideration in this scenario.
Structure of Isocitrate Dehydrogenase
Structurally, both IDH1 and IDH2 comprise three main domains:
the large domain, the small domain, and the clasp region (Yang
et al., 2010). A simplified description of protein motion is pro-
vided in Figure 3 (Rendina et al., 2013; Xu et al., 2004). The
dynamic of motion may differ slightly between IDH1 and IDH2
mutants. IDH1mutants appear to open wider than IDH2mutants
to the point of unwinding a helix termed ‘‘seg2’’ (Yang et al.,
2010). In contrast, the open form of IDH2 does not involve the
melting of any secondary structure, and as a consequence has
a much narrower range of motion (Taylor et al., 2008; Wang
et al., 2013). This differential in protein dynamics could possibly
explain the differential responses of IDH1 and IDH2 to inhibitors.
X-ray structures of IDH3 have not yet been reported, but it
appears to be distinct from IDH1 and IDH2 in terms of primary
sequence and predicted quaternary organization (Kim et al.,
1995; Ramachandran and Colman, 1980).
There are three arginine residues in the enzyme active site that
are predicted to play a central role in electrostatic stabilization
and proper geometric orientation of isocitrate via its acidic moi-
eties as the substrate binds in the active site. With the exception
of the novel G97D or G97N codon mutation (Ward et al., 2012),
virtually all confirmed IDH mutations that generate high levelsd All rights reserved
Chemistry & Biology
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IDH2-R172/R140) (Losman and Kaelin, 2013) and have in com-
mon a substitution of one of the diffuse positive charges of the
respective arginine’s guanidinium moiety.
Discovery of Inhibitors against Mutated Isocitrate
Dehydrogenase
Several inhibitors of mutant IDH isoforms that block 2HG pro-
duction in vitro and in vivo have been recently described. The
first potent and specific IDH1 inhibitors reported were the phe-
nylglycine series, specifically AGI-5198 (Popovici-Muller et al.,
2012; Rohle et al., 2013) and subsequently ML309 (Davis et al.,
2014) (Table 3), which were shown to be rapid-equilibrium inhib-
itors specific for IDH1-R132-codon mutations. These com-
pounds inhibited IDH1-R132H competitively with respect to
aKG and uncompetitively with respect to NADPH, suggesting
that they preferably bind to the enzyme-NADPH ternary com-
plex. Notably, they do not appreciably cross-react against the
IDH2-R140Q mutant isozyme, suggesting a unique binding
mode in IDH1-R132 that does not favorably exist in IDH2-
R140. Because no X-ray co-complex has been reported for
this series, the exact mode of binding cannot be ascertained at
this time. Preclinical data indicated 2HG inhibition and antitumor
effects in vitro and in vivo (Table 3). These phenylglycine com-
pounds appear to be excellent chemical tools for tumor biology
investigation, but optimization of their properties is likely
required for further therapeutic development.
Co-complexes of IDH1-R132H with two different 1-hydroxy-
pyridin-2-one inhibitors have been reported (Zheng et al.,
2013), but the quality of the crystal structure data supporting
the mechanism of inhibition is poor. AG-120, a selective, potent
inhibitor of mutated IDH1, is currently in clinical development for
the treatment of cancers with IDH1mutations (Table 3), but there
is currently no published information on this inhibitor. Another in-
hibitor of mutated IDH1 has been reported recently (Table 3)
(Deng et al., 2014). Co-complex X-ray studies revealed that
Compound 1 bindsmutated IDH1 allosterically at the dimer inter-
face resulting in an asymmetric open conformation. Distinctively,
Compound 1 displaces the conserved catalytic Tyr139 and
further disrupts theMg2+ binding network, consistent with kinetic
results of competitive inhibition with respect to Mg2+, but not
with aKG substrate. Others have reported modeling of inhibitors
into the active site of IDH1, but experimental evidence is lacking
(Chaturvedi et al., 2013; Davis et al., 2014).
The first reported potent and selective IDH2 inhibitor was the
urea-sulfonamide series, AGI-6780 (Wang et al., 2013), a time-
dependent slow-tight binder to IDH2-R140Q exhibiting noncom-
petitive inhibition with respect to substrate and uncompetitive
inhibition with respect to NADPH, and nanomolar potency for
2HG inhibition (Table 3). This compound showed good inhibitory
selectivity for IDH2-R140Q, with no effect on the closely related
IDH1 and IDH1-R132H isozymes. At doses that effectively
blocked 2HG to basal levels, AGI-6780 induced differentiation
of TF-1 erythroleukemia and primary human AML cells in vitro,
suggesting potential to reverse leukemic phenotype in AML
tumors harboring the IDH2 mutation. Unlike the case of IDH1
above, the published structure of AGI-6780 co-complexed with
IDH2-R140Q allows for detailed analysis of its inhibitory mecha-
nism (Wang et al., 2013). In the X-ray structure, a single moleculeChemistry & Biology 2of AGI-6780 binds at the interface of two protomers (Figure 2C).
The allosteric inhibition appears to arise from the ability of AGI-
6780 to keep the IDH2-R140Q mutant enzyme in an open orien-
tation, thereby preventing the NADPH cofactor and substrate
aKG from coming close to the catalytic Mg2+ binding site (see
Figure 3). The highly symmetric AGI-6780 binding pocket
extends deep into the protein interface and is closed over by
loops composed of residues 152–167, which also fold over
the binding pocket, providing an explanation for the time-depen-
dent inhibition kinetics. AGI-6780 makes several direct H-bond
interactions from its urea group and amide nitrogen to Gln316,
but a significant amount of binding energy arises from van
der Waals contacts between the protein and hydrophobic sur-
faces of AGI-6780. The in vivo potential for this compound is
not known, since its pharmacokinetic properties were not re-
ported. Nevertheless, this effective mode of inhibition serves
as an important molecular model for the design of bioisosteric
compounds.
Other IDH2 inhibitors are under development, notably AG-221,
a first-in-class, orally available inhibitor (Table 3) which demon-
strated a survival advantage in a preclinical study of a primary
human IDH2 mutant AML xenograft mouse model (Yen et al.,
2013). Early phase I clinical trial data for AG-221 show promise,
with meaningful clinical responses in evaluable AML patients
harboring IDH2 mutations (Stein et al., 2014). To date, there is
no published example of a molecule that inhibits both IDH1
and IDH2 mutant isoforms with equipotency.
Allostery as an Approach to Drugging Metabolic
Enzymes Is Important in Cancer
All enzymes discussed in this article are allosterically targeted
by small molecule modulators. With the exception of the en-
zymes of lipid metabolism, it is striking that there are very few
examples of the regulation of metabolic enzymes by drug-like
molecules at the catalytic site. We believe that this observation
will hold true for the wider set of metabolic enzymes. Metabolic
pathways are typically regulated by upstream and downstream
metabolites through feedforward and feedback mechanisms.
This regulation occurs typically through binding at allosteric
sites, which have distinctly different properties relative to
active sites. Therefore regulation can come from effectors
that may have very different properties to the substrate. This
review describes the potential therapeutic impact of spe-
cific allosteric regulators of PKM2, glutaminase, and IDH. Addi-
tionally, preclinical studies of tool compounds demonstrated
that allosteric regulators of other enzymes involved in cancer
cell metabolism could provide more therapeutic opportunities
(Table 4).
Substrates and products of metabolic enzymes tend to be
small and very polar, and often include crucial metal ions and
their ligands, so it is likely that targeting their catalytic pockets
will yield molecules with similar properties. From a drug-discov-
ery point of view, targeting allosteric sites is appealing as hydro-
philic substrate-binding sites are generally not hospitable to
strong interactions with small molecule drugs, which gain
potency to a large extent through hydrophobic interactions. In
addition, as activity of most metabolic enzymes is regulated by
multimerization, the formation of multimers provides opportunity
for binding sites to form at protein–protein interfaces, which1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1151
Table 3. Characteristics of Small Molecule Inhibitors of Mutant IDH
Class Drug Identifier Chemical Name and Structure Target Preclinical Data Clinical Data
Phenylglycine AGI-5198
(Popovici-Muller et al.,
2012; Rohle et al., 2013)
N-cyclohexyl-2-(N-(3-fluorophenyl)-2-
(2-methyl-1H-imidazol-1-yl)acetamido)-
2-(o-tolyl)acetamide
IDH1-R132H d Good potency against enzyme and in U87 cell
line overexpressing R132H mutation (IC50 =
70 nM)
d Good oral exposure in rodents at high doses
(>300 mg/kg), which were likely at levels
saturating hepatic clearance mechanisms
d Plasma 2HG inhibition >90% (BID dosing) in
xenograft model of U87-R132H tumors
d Promoted differentiation of glioma cells via
induced demethylation of histone H3K9me3 and
expression of genes associated with gliogenic
differentiation at near-complete 2HG inhibition
d Inhibited plasma 2HG and delayed growth
of IDH1-mutant but not wild-type glioma
xenografts in mice
-
ML309
(Davis et al., 2014)
2-(2-(1H-benzo[d]imidazol-1-yl)-N-(3-
fluorophenyl)acetamido)-N-cyclopentyl-
2-o-tolylacetamide
IDH1-R132H
IDH1-R132C
d IC50 = 68 nM (R132H)
d Inhibited 2HG production in glioblastoma cell
line (IC50 = 250 nM) with minimal cytotoxicity
-
1-hydroxypyridin-
2-one
Compounds 2 and 3
(Zheng et al., 2013)
6-substituted 1-hydroxypyridin-2-one IDH1-R132H
IDH1-R132C
d Ki = 190 and 280 nM (for R132H)
d Inhibited production of 2HG in IDH1-
mutated cells
Undisclosed AG-120
(Agios)
Undisclosed IDH1 d Orally available, selective, potent inhibitor d Phase I studies ongoing in
advanced solid tumors
(NCT02073994; NCT02074839)
(Continued on next page)
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Table 3. Continued
Class Drug Identifier Chemical Name and Structure Target Preclinical Data Clinical Data
Bis-imidazole phenol Compound 1
(Sanofi)
(Deng et al., 2014)
2,6-bis((1H-imidazol-1-yl)-4-(2,4,4-
trimethylpentan-2-yl)phenol
IDH1-R132H
IDH1-R132C
d Time-dependent inhibition
d Potency in the low nanomolar range (IC50 =
11 nM for R132H; 259 nM for R132C)
d Excellent selectivity for IDH1 mutations over
IDH2-mutated and wild-type enzymes
Urea-sulfonamide AGI-6780
(Agios)
(Wang et al., 2013)
(N-cyclopropyl-4-(thiophen-3-yl)-3-(3-
(3-(trifluoromethyl)phenyl)ureido)-
benzenesulfonamide)
IDH2-R140Q d Time-dependent, slow-tight binder
d Long residence time with measurable ON
and OFF rates
d Good potency in reducing 2HG in cell lines
overexpressing IDH2-R140Q (IC50 = 20 nM)
d Induced differentiation of TF-1
erythroleukemia and primary human AML cells
in vitro at doses that effectively block 2HG
to basal levels
Undisclosed AG-221
(Stein et al., 2014;
Yen et al., 2013)
Undisclosed IDH2 d Orally available, selective, potent inhibitor
d Reduced 2HG levels by >90% and reversed
histone and DNA hypermethylation in vitro
d In primary human AML mouse xenograft
model of IDH2-R140Q: potently reduced 2HG
in bone marrow, plasma and urine, induced
dose-dependent, statistically significant,
survival benefit, and dose-dependent
proliferative burst of human-specific CD45+
blast cells followed by cellular differentiation
that correlated with survival
d Mean plasma half-life >40 h
d Sustained reduction in 2HG
plasma levels of up to 97%
in patients with AML/MDS
d Objective responses in 6 of
10 evaluable AML patients
(2 CRa)
d Responses associated with
marked differentiation of
myeloblasts into mature forms
d No dose-limiting toxicities
d Possible drug-related SAEs
in 2 of 19 patients (grade 2
hyperleukocytosis and grade
3 confusion)
aComplete remissions as defined by the International Working Group Criteria. MDS, myelodysplastic syndrome; SAE, serious adverse event.
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Table 4. Examples of Allostery in Cancer Cell Metabolism
Symbol Description Regulator Inhibitor/Activator Metabolic Pathway Reference
TH Tyrosine hydroxylase Haloperidol Activator Catecholamine
metabolism
(Casu and Gale, 1981)
PDK1 Pyruvate dehydrogenase
kinase isozyme 1
3,5-diphenylpent-2-enoic acids Activator TCA cycle (Stroba et al., 2009)
BCKDK Branched chain ketoacid
dehydrogenase kinase
(S)-a-chloro-phenylpropionic acid [(S)-CPP] Inhibitor Branch-chain
amino acid
(Tso et al., 2013)
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Table 4. Continued
Symbol Description Regulator Inhibitor/Activator Metabolic Pathway Reference
ACACA Acetyl-CoA carboxylase
alpha
5-tetradecyloxy-2-furoic acid (TOFA) Inhibitor Fatty acid synthesis (Wang et al., 2009)
FBP1 Fructose-1,6-
bisphosphatase 1
Benzoxazole benzenesulfonamide 1 Inhibitor Glycolysis (von Geldern et al., 2006)
ALAD Aminolevulinate
dehydratase
wALADin1 benzimidazoles Inhibitor Haem synthesis (Lentz et al., 2014)
TYR Tyrosinase 2,3-dithiopropanol Inhibitor Melanin metabolism (Wood and Schallreuter,
1991)
(Continued on next page)
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Table 4. Continued
Symbol Description Regulator Inhibitor/Activator Metabolic Pathway Reference
DBH Dopamine beta-
hydroxylase
-2H-phthalazine hydrazone
(hydralazine; HYD)
2-1H-pyridinone hydrazone (2-hydrazinopyridine; HP)
2-quinoline-carboxylic acid (QCA)
1H-imidazole-4-acetic acid (imidazole-4-acetic acid; IAA)
Inhibitor Neurotransmitter
synthesis
(Townes et al., 1990)
(Continued on next page)
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Table 4. Continued
Symbol Description Regulator Inhibitor/Activator Metabolic Pathway Reference
DCTD dCMP deaminase 5-iodo-2’-deoxyuridine 5’-triphosphate Inhibitor Nucleotide
metabolism
(Prusoff and Chang,
1968)
TYMP Thymidine
phosphorylase
5’-O-tritylinosine (KIN59) Inhibitor Nucleotide meta olism (Casanova et al., 2006)
TYMS Thymidylate
synthase
1,3-propanediphosphonic acid (PDPA) Inhibitor Nucleotide meta olism (Lovelace et al., 2007)
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Chemistry & Biology
Reviewcould confer allosteric target modulation. Indeed, all four pro-
teins discussed in this review have small molecule modulators
that bind at multimer interfaces. For the examples we show
here, the properties of the compounds that target these pockets
are well within the boundaries of drug-likeness, and as described
above, some are already in clinical development.Future Directions
Cancer metabolism as a therapeutic concept provides a wealth
of novel targets for discovery and development. Equally impor-
tant, it provides new perspectives and insights into well known
targets with respect to optimizing drug combination strategies
and improved stratification of potential clinical response. The
efficacy of asparaginase as part of the chemotherapy regimen
in acute lymphoblastic leukemia validates the importance of
metabolism in cancer. The new targets are exemplified by the
more advanced glutaminase and mutant IDH1/2 inhibitors that
have just entered the clinical testing phase. Compelling clinical
responses demonstrated by a mutant IDH2 inhibitor as single-
agent therapy in advanced and relapsed AML serves to solidify
cancer metabolism as an important therapeutic concept (Stein
et al., 2014).
Although cancer metabolism may offer vast therapeutic po-
tential, many challenges remain. Beyond the identification of
metabolic enzymes with recurrent mutations, such as those
seen in IDH1/2, the targeting of nonmutated essential metabolic
enzymes is an area of intense focus. This effort requires an
extensive bioinformatics-driven understanding of genetic,
epigenetic, and metabolic networks, accompanied by early
access to high quality primary samples in order to clearly define
patient responders. From a biological standpoint, metabolic
adaptation under changing nutrient conditions poses a major
technical challenge in translating in vitro findings to the clinic.
Methods allowing the study of whole-animal in vivo tumor meta-
bolism are required to help uncover cancer susceptibility and
move toward validation of drug targets. Finally, the challenges
of drugging metabolic enzymes are well highlighted in this re-
view. It has been difficult to discover potent active-site inhibitors
that also have good drug properties, given the exquisite sub-
strate-selective nature of these well evolved enzymes. Instead,
we and others have found allostericmodulation to be an effective
approach to designing drug-like small molecules against dif-
ferent metabolic enzyme classes. This approach exploits native
allosteric modulator sites and interdomain pockets of multimeric
tertiary architecture, features typical of central metabolic en-
zymes. Some of these allosteric sites could be predicted from
apo-enzyme or substrate-bound X-ray structures, but more
often are revealed only through screening chemical libraries of
small molecules. Despite these challenges, and with advances
in genomics and epigenomics, cancer metabolism has now
arrived at an exciting stage that is full of promise for transforming
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